| Project/Area Number |
16K19714
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
池谷 茂樹 浜松医科大学, 医学部附属病院, 助教 (40436936)
|
|---|
| Project Period (FY) |
2016-04-01 – 2017-03-31
|
| Project Status |
Discontinued (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | ボリコナゾール / 光線性皮膚癌 / 芳香族炭化水素受容体 / COX-2 / 活性酸素 / 皮膚癌 / 芳香族炭化水素 |
|---|
| Outline of Annual Research Achievements |
Voriconazole (VRCZ) induces the development of UV-associated skin cancers. The mechanism underlying the VRCZ-induced carcinogenesis has been largely unknown.
Clinical studies (VRCZ-induced skin tumors were clinically summarized, and VRCZ-induced actinic keratosis (AK) were histopathologically compared with ordinary AK) suggested that VRCZ can strongly evoke the tumor formation of keratinocytes (KC)s under a certain immunocompromised condition and its tumorigenesis is not simply caused by photosensitivity. In vitro, we showed that VRCZ metabolites plus UVA generated reactive oxygen species and resultant DNA damage of the epidermis, but did not induce substantial apoptosis in KCs. Furthermore, VRCZ per se stimulates aryl hydrocarbon receptor (AhR) and upregulates COX-2, which is a pivotal enzyme for the promotion of UV-associated tumors, in an AhR-ARNT dependent manner of the classical (genomic) pathway.
Our findings suggest that VRCZ primarily promotes the tumor development of preexisted UV-damaged KCs in clinical settings, while the phototoxic moieties of VRCZ metabolites may participate in the initiation phase.
|
